US Patent Issued to Board of Regents, The University of Texas System on June 3 for "Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)" (Texas Inventors)

ALEXANDRIA, Va., June 4 -- United States Patent no. 12,319,744, issued on June 3, was assigned to Board of Regents, The University of Texas System (Austin, Texas).

"Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)" was invented by Vijaya M. Lella (Tyler, Texas), Usha R. Pendurthi (Tyler, Texas) and Jhansi L. Magisetty (Tyler, Texas).

According to the abstract* released by the U.S. Patent & Trademark Office: "An antibody, preferably a blocking antibody, and most preferably a monoclonal antibody (mAb), specific for human endothelial cell protein C receptor (EPCR) such as mAbs JRK 1494 or JRK 1535 is used to reduce or attenuate joint swelling, macrophage infiltration, iron...